Search results
What to Know About Spinal Muscular Atrophy (SMA)
Verywell Health via Yahoo News· 9 months agoNew treatments have improved outlookMedically reviewed by Nicholas R. Metrus, MD Spinal muscular atrophy (SMA) is a genetic disease that causes muscle...
Twin 'was just melting': Babies with neuromuscular disease find new hope in Austin
Austin American-Statesman via Yahoo News· 2 years agoJenny and Jarod Carter's twins weren't making their typical infant milestones after they were born...
Spinal Muscular Atrophy (SMA): New Treatments Offer Hope
The Today Show via AOL· 2 years agoAt her eight-month pregnancy check-up, Lizmara Figueroa met with a new doctor. As he walked out the...
Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns
Zacks via Yahoo Finance· 10 months agoRoche RHHBY announced that the European Commission (“EC”) had approved the label expansion for...
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
Zacks via Yahoo Finance· 2 years agoBiohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted...
Most babies with this rare genetic disease are on ventilators by 8 months. This Austin baby beat the...
Austin American-Statesman via Yahoo News· 2 years agoNoah Strauch loves to laugh. He loves to put things into a bucket and dump them out again. He crawls...
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
Zacks via Yahoo Finance· 4 months agoIonis Pharmaceuticals IONS reported a loss of 6 cents per share for fourth-quarter 2023, which was...
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
Zacks via Yahoo Finance· 10 months agoIonis Pharmaceuticals IONS reported a loss of 60 cents per share for second-quarter 2023, which was...
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
Benzinga via Yahoo Finance· 2 years agoRoche Holdings AG (OTC: RHHBY) announced new two-year data from the JEWELFISH study evaluating...
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
Zacks via Yahoo Finance· 2 years agoIonis Pharmaceuticals IONS reported second-quarter 2022 loss of 74 cents per share, which was wider...